Цибисатамаб

Rec. INN (наименование, зарегистрированное ВОЗ)

USAN (наименование, принятое к употреблению в США)

1855925-27-7

immunoglobulin G1-kappa/lambda with domain crossover, anti-[Homo sapiens CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5, CEA, CD66e)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], humanized monoclonal antibody, bispecific, trivalent;
gamma-kappa heavy chain anti-CEACAM5 and anti-CD3E (VH-CH1-VH-C-kappa-CH2-CH3) (1-694)  [humanized VH anti-CEACAM5 (Homo sapiens IGHV1-18*01 (82.7%) -(IGHD) -IGHJ4*01 (92.3%)) [8.8.14] (1-121) -Homo sapiens IGHG1*01, G1m17 (CH1 K120 (218) (122-219), hinge 1-6 (220-225)) (122-225) -10-mer bis(tetraglycyl-seryl) linker (226-235) -humanized VH anti-CD3E (Homo sapiens IGHV3-23*03 (87.0%) -(IGHD) -IGHJ6*01 (90.9%)) [8.10.16] (236-360) -Homo sapiens IGKC*01, R1.4>S (361), Km3 A45.1 (406), V101 (444) (361-467) -Homo sapiens IGHG1*01, G1m1 (hinge 5-15 (467-477), CH2 [L1.3>A (481), L1.2>A (482), P114>G (576)] (478-587), CH3 D12 (603), L14 (605) [S10>C (601), T22>W (613)] (588-692), CHS (693-694)) (468-694)];  (224-215''')-disulfide with kappa light chain anti-CEACAM5 (1'''-215''') [humanized V-KAPPA (Homo sapiens IGKV1-16*01 (82.1%) -IGKJ2*02 (100%)) [6.3.10] (1'''-108''') -Homo sapiens IGKC*01 Km3 A45.1 (154), V101 (192) (109'''-215''')]; (467-214')-disulfide with lambda-gamma light chain anti-CD3E (1'-214') [V-LAMBDA (Mus musculus IGLV1*01 (81.2%) -IGLJ1*01 (100%)/Homo sapiens IGLV7-46*01 (80%) -IGLJ3*01 (100%)) [9.3.9] (1'-109') -2-mer biseryl linker (110'-111') -Homo sapiens IGHG1*01, G1m17 (CH1 K120 (208) (112'-209') -hinge 1-5 (210'-214'))];
gamma1 heavy chain anti-CEACAM5 (1''-451'') [humanized VH (Homo sapiens IGHV1-18*01 (82.7%) -(IGHD) -IGHJ4*01 (92.3%)) [8.8.14] (1''-121'') -Homo sapiens IGHG1*01, G1m17 (CH1 K120 (218) (122-219), hinge 1-15 (220-234), CH2 [L1.3>A (238), L1.2>A (239), P114>G (333)] (235-344), CH3 [Y5>C (353), T22>S (370), L24>A (372), Y86>V (411)] (345-449), CHS (450-451)) (122''-451'')]; (224''-215''')-disulfide with kappa light chain anti-CEACAM5 (1'''-215''') [humanized V-KAPPA (Homo sapiens IGKV1-16*01 (82.1%) -IGKJ2*02 (100%)) [6.3.10] (1'''-108''') -Homo sapiens IGKC*01 Km3 A45.1 (154), V101 (192) (109'''-215''')]; dimer (473-230'':476-233'':601-353'')-trisdisulfide

Поделиться этой страницей